Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Farnesyl diphosphate synthase

4

Hydroxyapatite crystals

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1998

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Glucocorticoid-induced osteoporosis

4

Increase bone mass in men with osteoporosis

4

Paget’s disease of bone

4

Postmenopausal osteoporosis

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Procter & Gamble

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

DAILYMED

4

DRUG BANK

4

FDA UNII

4

PUBCHEM

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR TREATMENT OF BONE DISEASES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Bisphosphonates

1

Bisphosphonates, combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

RISEDRONIC ACID

KM2Z91756Z

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1998

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hydroxyapatite crystals

Farnesyl diphosphate synthase

Conditions:

Paget’s disease of bone

Postmenopausal osteoporosis

Glucocorticoid-induced osteoporosis

Increase bone mass in men with osteoporosis

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral m...

atrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

RISEDRONATE SODIUM MONOHYDRATE

F67L43UT5C

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1998

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hydroxyapatite crystals

Farnesyl diphosphate synthase

Conditions:

Paget’s disease of bone

Postmenopausal osteoporosis

Glucocorticoid-induced osteoporosis

Increase bone mass in men with osteoporosis

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral m...

atrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

RISEDRONATE SODIUM HEMI-PENTAHYDRATE

HU2YAQ274O

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1998

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hydroxyapatite crystals

Farnesyl diphosphate synthase

Conditions:

Paget’s disease of bone

Postmenopausal osteoporosis

Glucocorticoid-induced osteoporosis

Increase bone mass in men with osteoporosis

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral m...

atrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

RISEDRONATE SODIUM

OFG5EXG60L

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1998

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hydroxyapatite crystals

Farnesyl diphosphate synthase

Conditions:

Paget’s disease of bone

Postmenopausal osteoporosis

Glucocorticoid-induced osteoporosis

Increase bone mass in men with osteoporosis

Risedronic acid is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral m...

atrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. It is FDA approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis and Paget’s disease. Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of Risedronic acid. Common adverse reactions include rash, abdominal pain, constipation, diarrhea, indigestion, nausea, backache, urinary tract infectious disease and influenza-like illness.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1